Share on LinkedInShare on LinkedIn

ARTICLE · 30 MARCH 2021

A US Perspective – Should The Patent Procurement Process Fall Under The Remit Of Antitrust Law?

Bristows LLP
Bristows LLP
Contributor
Bristows LLP

Bristows LLP

We are Bristows, the world’s leading specialist law firm for clients that innovate. We are a London...

View firm profile
Explore more from Bristows LLP

An amicus curiae brief recently filed by the US Department of Justice ("DoJ") has provided insight into the evolving US position on this grey area of antitrust law.

United StatesAntitrust/Competition Law

An amicus curiae brief recently filed by the US Department of Justice ("DoJ") has provided insight into the evolving US position on this grey area of antitrust law.

An antitrust suit filed against AbbVie and biosimilar companies on behalf of indirect US purchasers of Humira claimed Abbvie's strategy of filing of over 100 patents for Humira amounted to a 'patent thicket'. The decision was appealed to the US Court of Appeals after being dismissed in its entirety at first instance and the DoJ has now submitted an amicus curiae brief. In this brief, the DoJ has clearly set out its view on the lawfulness of 'patent thickets' and has suggested that deficiencies in the patent system should not "be remedied by antitrust law".

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

See more popular content from